> top > docs > PubMed:23065705 > annotations

PubMed:23065705 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 0-6 D010770 denotes Kinase
T2 7-17 CHEBI:35222 denotes inhibitors
T3 76-81 PR:Q5S006 denotes LRRK2
T4 76-81 PR:000003033 denotes LRRK2
T5 76-81 PR:Q5S007 denotes LRRK2
T7 105-112 6308 denotes leucine
T8 105-112 SO:0001437 denotes leucine
T6 105-112 CHEBI:15603 denotes leucine
T9 105-112 D007930 denotes leucine
T10 105-112 CHEBI:25017 denotes leucine
T11 105-112 D007930 denotes leucine
T12 118-124 SO:0001068 denotes repeat
T13 135-140 PR:Q5S006 denotes LRRK2
T14 135-140 PR:000003033 denotes LRRK2
T15 135-140 PR:Q5S007 denotes LRRK2
T16 179-189 D000067562 denotes late-onset
T17 179-189 D000067562 denotes late-onset
T22 190-209 D010300 denotes Parkinson's disease
T23 190-209 D010300 denotes Parkinson's disease
T26 262-271 CHEBI:25367 denotes molecules
T27 286-291 PR:Q5S006 denotes LRRK2
T28 286-291 PR:000003033 denotes LRRK2
T29 286-291 PR:Q5S007 denotes LRRK2
T30 299-305 SO:0000417 denotes domain
T31 328-333 PR:Q5S006 denotes LRRK2
T32 328-333 PR:000003033 denotes LRRK2
T33 328-333 PR:Q5S007 denotes LRRK2
T34 341-351 CHEBI:35222 denotes inhibitors
T36 353-361 C588240 denotes TTT-3002
T37 353-361 CHEBI:88219 denotes TTT-3002
T38 353-361 C588240 denotes TTT-3002
T39 366-371 PR:Q5S006 denotes LRRK2
T40 366-371 PR:000003033 denotes LRRK2
T41 366-371 PR:Q5S007 denotes LRRK2
T42 366-375 CHEBI:78413 denotes LRRK2-IN1
T43 366-375 C582847 denotes LRRK2-IN1
T44 366-375 C582847 denotes LRRK2-IN1
T45 372-375 CVCL_W473 denotes IN1
T46 403-408 PR:Q5S006 denotes LRRK2
T47 403-408 PR:000003033 denotes LRRK2
T48 403-408 PR:Q5S007 denotes LRRK2
T50 434-456 D017173 denotes Caenorhabditis elegans
T51 434-456 6239 denotes Caenorhabditis elegans
T52 467-472 PR:Q5S006 denotes LRRK2
T53 467-472 PR:000003033 denotes LRRK2
T54 467-472 PR:Q5S007 denotes LRRK2
T56 499-507 C588240 denotes TTT-3002
T57 499-507 CHEBI:88219 denotes TTT-3002
T58 499-507 C588240 denotes TTT-3002
T59 512-517 PR:Q5S006 denotes LRRK2
T60 512-517 PR:000003033 denotes LRRK2
T61 512-517 PR:Q5S007 denotes LRRK2
T62 512-521 CHEBI:78413 denotes LRRK2-IN1
T63 512-521 C582847 denotes LRRK2-IN1
T64 512-521 C582847 denotes LRRK2-IN1
T65 518-521 CVCL_W473 denotes IN1
T66 550-565 GO:0016301 denotes kinase activity
T67 569-574 PR:Q5S006 denotes LRRK2
T68 569-574 PR:000003033 denotes LRRK2
T69 569-574 PR:Q5S007 denotes LRRK2
T70 575-584 SO:0000817 denotes wild-type
T71 589-604 D050505 denotes mutant proteins
T73 617-632 GO:0016310 denotes phosphorylation
T74 645-650 PR:Q5S006 denotes LRRK2
T75 645-650 PR:000003033 denotes LRRK2
T76 645-650 PR:Q5S007 denotes LRRK2
T77 687-692 PR:Q5S006 denotes LRRK2
T78 687-692 PR:000003033 denotes LRRK2
T79 687-692 PR:Q5S007 denotes LRRK2
T80 736-741 PR:Q5S006 denotes LRRK2
T81 736-741 PR:000003033 denotes LRRK2
T82 736-741 PR:Q5S007 denotes LRRK2
T83 749-759 CHEBI:35222 denotes inhibitors
T84 773-785 GO:0009405 denotes pathogenesis
T85 878-883 PR:Q5S006 denotes LRRK2
T86 878-883 PR:000003033 denotes LRRK2
T87 878-883 PR:Q5S007 denotes LRRK2
T88 891-897 SO:0000417 denotes domain
T90 937-945 C588240 denotes TTT-3002
T91 937-945 CHEBI:88219 denotes TTT-3002
T92 937-945 C588240 denotes TTT-3002
T93 950-955 PR:Q5S006 denotes LRRK2
T94 950-955 PR:000003033 denotes LRRK2
T95 950-955 PR:Q5S007 denotes LRRK2
T96 950-959 CHEBI:78413 denotes LRRK2-IN1
T97 950-959 C582847 denotes LRRK2-IN1
T98 950-959 C582847 denotes LRRK2-IN1
T99 956-959 CVCL_W473 denotes IN1
T101 1035-1043 C588240 denotes TTT-3002
T102 1035-1043 CHEBI:88219 denotes TTT-3002
T103 1035-1043 C588240 denotes TTT-3002
T104 1048-1053 PR:Q5S006 denotes LRRK2
T105 1048-1053 PR:000003033 denotes LRRK2
T106 1048-1053 PR:Q5S007 denotes LRRK2
T107 1048-1057 CHEBI:78413 denotes LRRK2-IN1
T108 1048-1057 C582847 denotes LRRK2-IN1
T109 1048-1057 C582847 denotes LRRK2-IN1
T110 1054-1057 CVCL_W473 denotes IN1
T111 1134-1144 SO:0000781 denotes transgenic
T112 1167-1172 D006801 denotes human
T113 1192-1197 PR:Q5S006 denotes LRRK2
T114 1192-1197 PR:000003033 denotes LRRK2
T115 1192-1197 PR:Q5S007 denotes LRRK2
T116 1203-1213 CHEBI:35222 denotes inhibitors
T117 1252-1258 SO:0000814 denotes rescue
T119 1292-1295 PR:Q8LLD0 denotes pre
T120 1292-1295 SO:0002045 denotes pre
T121 1292-1295 UBERON:0001782 denotes pre
T118 1292-1295 GO:0003904 denotes pre
T122 1466-1472 SO:0000814 denotes rescue
T124 1508-1516 C588240 denotes TTT-3002
T125 1508-1516 CHEBI:88219 denotes TTT-3002
T126 1508-1516 C588240 denotes TTT-3002
T127 1521-1526 PR:Q5S006 denotes LRRK2
T128 1521-1526 PR:000003033 denotes LRRK2
T129 1521-1526 PR:Q5S007 denotes LRRK2
T130 1521-1530 CHEBI:78413 denotes LRRK2-IN1
T131 1521-1530 C582847 denotes LRRK2-IN1
T132 1521-1530 C582847 denotes LRRK2-IN1
T133 1527-1530 CVCL_W473 denotes IN1
T134 1560-1577 D019636 denotes neurodegenerative
T135 1560-1577 D019636 denotes neurodegenerative
T136 1591-1601 SO:0000781 denotes transgenic
T137 1621-1630 CHEBI:35222 denotes inhibitor
T138 1648-1656 SO:0000109 denotes mutation
T139 1660-1665 PR:Q5S006 denotes LRRK2
T140 1660-1665 PR:000003033 denotes LRRK2
T141 1660-1665 PR:Q5S007 denotes LRRK2
T142 1695-1718 D018696 denotes neuroprotective effects
T143 1695-1718 D018696 denotes neuroprotective effects
T144 1740-1745 PR:Q5S006 denotes LRRK2
T145 1740-1745 PR:000003033 denotes LRRK2
T146 1740-1745 PR:Q5S007 denotes LRRK2
T147 1791-1796 PR:Q5S006 denotes LRRK2
T148 1791-1796 PR:000003033 denotes LRRK2
T149 1791-1796 PR:Q5S007 denotes LRRK2
T150 1797-1812 GO:0016301 denotes kinase activity
T151 1923-1928 PR:Q5S006 denotes LRRK2
T152 1923-1928 PR:000003033 denotes LRRK2
T153 1923-1928 PR:Q5S007 denotes LRRK2

DisGeNET

Id Subject Object Predicate Lexical cue
T0 1521-1526 gene:120892 denotes LRRK2
T1 1602-1607 disease:C0018889 denotes worms
T2 1660-1665 gene:120892 denotes LRRK2
T3 1602-1607 disease:C0018889 denotes worms
R1 T0 T1 associated_with LRRK2,worms
R2 T2 T3 associated_with LRRK2,worms

Allie

Id Subject Object Predicate Lexical cue
SS1_23065705_1_0 105-133 expanded denotes leucine-rich repeat kinase 2
SS2_23065705_1_0 135-140 abbr denotes LRRK2
SS1_23065705_1_1 190-209 expanded denotes Parkinson's disease
SS2_23065705_1_1 211-213 abbr denotes PD
AE1_23065705_1_0 SS1_23065705_1_0 SS2_23065705_1_0 abbreviatedTo leucine-rich repeat kinase 2,LRRK2
AE1_23065705_1_1 SS1_23065705_1_1 SS2_23065705_1_1 abbreviatedTo Parkinson's disease,PD

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 92-215 DRI_Approach denotes Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent known cause of late-onset Parkinson's disease (PD).
T2 216-498 DRI_Outcome denotes To explore the therapeutic potential of small molecules targeting the LRRK2 kinase domain, we characterized two LRRK2 kinase inhibitors, TTT-3002 and LRRK2-IN1, for their effects against LRRK2 activity in vitro and in Caenorhabditis elegans models of LRRK2-linked neurodegeneration.
T3 499-714 DRI_Background denotes TTT-3002 and LRRK2-IN1 potently inhibited in vitro kinase activity of LRRK2 wild-type and mutant proteins, attenuated phosphorylation of cellular LRRK2 and rescued neurotoxicity of mutant LRRK2 in transfected cells.
T4 715-1034 DRI_Approach denotes To establish whether LRRK2 kinase inhibitors can mitigate pathogenesis caused by different mutations including G2019S and R1441C located within and outside of the LRRK2 kinase domain, respectively, we evaluated effects of TTT-3002 and LRRK2-IN1 against R1441C- and G2019S-induced neurodegeneration in C. elegans models.
T5 1035-1198 DRI_Challenge denotes TTT-3002 and LRRK2-IN1 rescued the behavioral deficit characteristic of dopaminergic impairment in transgenic C. elegans expressing human R1441C- and G2019S-LRRK2.
T6 1199-1405 DRI_Background denotes The inhibitors displayed nanomolar to low micromolar rescue potency when administered either pre-symptomatically or post-symptomatically, indicating both prevention and reversal of the dopaminergic deficit.
T7 1406-1494 DRI_Background denotes The same treatments also led to long-lasting prevention and rescue of neurodegeneration.
T8 1495-1620 DRI_Background denotes In contrast, TTT-3002 and LRRK2-IN1 were ineffective against the neurodegenerative phenotype in transgenic worms carrying the
T9 1648-1759 DRI_Background denotes mutation of LRRK2, suggesting that they elicit neuroprotective effects in vivo by targeting LRRK2 specifically.
T10 1760-1983 DRI_Outcome denotes Our findings indicate that the LRRK2 kinase activity is critical for neurodegeneration caused by R1441C and G2019S mutations, suggesting that kinase inhibition of LRRK2 may represent a promising therapeutic strategy for PD.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 190-199 HP_0001300 denotes Parkinson
T2 480-497 HP_0002180 denotes neurodegeneration
T3 995-1012 HP_0002180 denotes neurodegeneration
T4 1476-1493 HP_0002180 denotes neurodegeneration
T5 1829-1846 HP_0002180 denotes neurodegeneration

DisGeNET5_variant_disease

Id Subject Object Predicate Lexical cue
23065705-9#108#114#geners34637584 1868-1874 geners34637584 denotes G2019S
23065705-9#220#222#diseaseC3160718 1980-1982 diseaseC3160718 denotes PD
108#114#geners34637584220#222#diseaseC3160718 23065705-9#108#114#geners34637584 23065705-9#220#222#diseaseC3160718 associated_with G2019S,PD

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
23065705-9#31#36#gene120892 1791-1796 gene120892 denotes LRRK2
23065705-9#163#168#gene120892 1923-1928 gene120892 denotes LRRK2
23065705-9#220#222#diseaseC3160718 1980-1982 diseaseC3160718 denotes PD
31#36#gene120892220#222#diseaseC3160718 23065705-9#31#36#gene120892 23065705-9#220#222#diseaseC3160718 associated_with LRRK2,PD
163#168#gene120892220#222#diseaseC3160718 23065705-9#163#168#gene120892 23065705-9#220#222#diseaseC3160718 associated_with LRRK2,PD